ReviewJournal of pain research2026
Efficacy of Pulsed Radiofrequency Combination Therapy for Postherpetic Neuralgia: A Systematic Review and Bayesian Network Meta-Analysis.
Review in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postherpetic neuralgia (PHN) lowers quality of life. However, the comparative efficacy of pulsed radiofrequency (PRF)-based combination therapies remains unclear. This study compared different PRF combination regimens for PHN. Methods: Eight databases were searched up to July 25, 2025. Risk of bias was assessed using the Cochrane RoB 2 and the Newcastle‑Ottawa Scale. Pain was the primary outcome; sleep, anxiety, and depression were secondary. A Bayesian network meta‑analysis was performed in R (version 4.4.1), with effect sizes expressed as mean differences (MDs) or standardized mean differences (SMDs), alongside 95% credible intervals (CrIs) and surface under the cumulative ranking curve (SUCRA) values. Results: Seventeen studies were included. For pain relief, PRF + radiofrequency ablation (RFA) (MD = -2.1, 95% CrI: [-2.7, -1.5], SUCRA = 0.96) was the optimal regimen at one week, while PRF+glucocorticoid (GC) was superior at around one month (MD = -2.3, 95% CrI: [-2.6, -1.9], SUCRA = 0.96) and at three months (MD = -2.3, 95% CrI: [-2.7, -2.0], SUCRA = 0.97). Regarding sleep, PRF + intravenous lidocaine infusion (SMD = -9.2, 95% CrI: [-11, -7.5], SUCRA = 0.99) was most effective at one week, whereas PRF+duloxetine (SMD = -1.5, 95% CrI: [-2.0, -1.1], SUCRA = 0.98) was superior at three months. Anxiety was most effectively alleviated by PRF + intravenous lidocaine infusion (SMD = -1.6, 95% CrI: [-2.1, -1.0], SUCRA = 0.94). PRF+duloxetine (SMD = -2.5, 95% CrI: [-3.1, -2.0], SUCRA = 0.99) was the optimal combination for mitigating depression. Conclusion: PRF+RFA may be the optimal combination for pain relief at one week, and PRF+GC appears more effective at around one month and over longer follow-up. Lidocaine infusion may benefit sleep at one week and anxiety, while duloxetine may enhance longer-term sleep and alleviate depression. Additional trials are warranted. Trial Number: CRD420251155850.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.